AAVantgarde Bio
Milan, Lombardy, Italy · Biotechnology, Genetics, Health Care
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Key facts
- Headquarters
- Milan, Lombardy, Italy
- Employees
- 48
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Private
- Website
- aavantgarde.com
- Company page
Recent activity at AAVantgarde Bio
AAVantgarde Bio funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Series B | $141.0M |
Leadership
- Claudio Spera, Vice President of Medical Affairs, Ophthalmology
- Malcolm Horsley, Vice President Project Management and Information Technology
- Ioulietta Mulligan, VP Biometrics & Clinical Technologies
- Nina Kotsopoulou, Chief Technical Officer
- Jayashree Sahni, Chief Medical Officer
- Nina Kotsopoulou, Chief Technology Officer
- Magdalena Blanco, Not Provided
- Fabrizio Comper, Innovator In Protein Engineering
- Cindy Nguyen, Head of Operations and Compliance
- James Mcphie, Sas Programmer
- Alberto Auricchio, Founder
- Tessa Verbanic Brandon, Director, Regulatory Affairs
Verified email and direct lines for AAVantgarde Bio’s decision-makers are on Fundz. See plans
AAVantgarde Bio in the news
- AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081 - Ophthalmology Times (Nov 25, 2025)
- Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials - Fierce Biotech (Nov 03, 2025)
- Beyond BioNTech: Inside the Strüngmann Portfolio in 2026 (Antheia, AAVantgarde, Doctolib, and the Next Decade) - Startuprad Io (May 06, 2026)
- FDA grants fast track designation to AAVantgarde Bio for AAVB-039 - Ophthalmology Times (Aug 12, 2025)
- AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies - Ophthalmology Times (May 16, 2025)
- AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA - Ophthalmology Times (Oct 03, 2025)
Companies similar to AAVantgarde Bio
- Applied StemCell · Biotechnology, Genetics, Health Care, research, Therapeutics
- Takis S.r.l · Biotechnology, Health Care, research, Therapeutics
- Typewriter Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Epicrispr Biotechnologies · Biotechnology, Genetics, Health Care, Therapeutics
- Rezo Therapeutics · Biotechnology, Genetics, Health Care, research
About AAVantgarde Bio: questions and answers
What does AAVantgarde Bio do?
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Where is AAVantgarde Bio headquartered?
AAVantgarde Bio is headquartered in Milan, Lombardy, Italy.
How many employees does AAVantgarde Bio have?
AAVantgarde Bio has about 48 employees.
Has AAVantgarde Bio raised funding?
Yes. Fundz has recorded 1 funding event for AAVantgarde Bio. The most recent, Series B of $141.0M, was in Nov 2025.
Who leads AAVantgarde Bio?
Claudio Spera is a Vice President of Medical Affairs, Ophthalmology at AAVantgarde Bio.
What is the latest news on AAVantgarde Bio?
On Nov 03, 2025, AAVantgarde secures $141m Series B funding to advance its gene therapies for inherited retinal diseases.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy